Why MacroGenics, Inc. Stock Soared Today
Shares of the clinical-stage oncology and autoimmune disease specialist MacroGenics (NASDAQ: MGNX) ended the day higher by a healthy 17.36% on a whopping 17.5 times the average volume.
The catalyst? Macrogenics' shares took flight after the company announced a licensing deal with Incyte Corp. (NASDAQ: INCY) for its programmed cell-death protein 1 (PD-1) inhibitor, MGA012, that's being assessed in four solid tumor types in an early-stage dose-escalation study.
Image source: Getty Images.
Source: Fool.com
Incyte Corp. Aktie
103,90 €
-0,67 %
Die Incyte Corp. Aktie genießt hohe Beliebtheit: Mehr Buy- (26) als Sell-Einschätzungen (1).
Ein leicht positives Potenzial wird für Incyte Corp. mit einem Kursziel von 114 € im Vergleich zu 103.9 € gesehen.
